Aura Biosciences, Inc. Common Stock
AURA
AURA: Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long-lasting anti-tumor immunity.
moreShow AURA Financials
Recent trades of AURA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AURA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Virus-like particle conjugates for diagnosis and treatment of tumors Sep. 07, 2021
-
Patent Title: Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells Mar. 24, 2020
-
Patent Title: Virus-like particle conjugates for diagnosis and treatment of tumors Mar. 17, 2020
-
Patent Title: Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells May. 28, 2019
-
Patent Title: Virus-like particle conjugates for diagnosis and treatment of tumors Nov. 06, 2018
-
Patent Title: Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells Jan. 02, 2018
-
Patent Title: Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells Jul. 11, 2017
Federal grants, loans, and purchases
Followers on AURA's company Twitter account
Number of mentions of AURA in WallStreetBets Daily Discussion
Recent insights relating to AURA
Recent picks made for AURA stock on CNBC
ETFs with the largest estimated holdings in AURA
Flights by private jets registered to AURA